Participant flow

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL · Source last updated 2017-11-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Ibrutinib 420 mg daily.

   id

   FG000

   title

   Ibrutinib

2. description

   Chlorambucil 0.5 mg/kg (to maximum 0.8 mg/kg) days 1 and 15 of 28-day cycle up to 12 cycles

   id

   FG001

   title

   Chlorambucil

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         136

      2. group Id

         FG001

         num Subjects

         133

      type

      STARTED

   2. achievements

      1. comment

         Participants who were still on study or died at study closure

         group Id

         FG000

         num Subjects

         134

      2. comment

         Participants who were still on study or died at study closure

         group Id

         FG001

         num Subjects

         126

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         2

      2. group Id

         FG001

         num Subjects

         7

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice